Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT02762006 trial: what clinicians have said so far
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
- NCT02762006 ↗
- Completed
- Moshe Ornstein
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT02762006 (durvalumab plus tremelimumab in locally advanced renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02762006 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Renal Cell Carcinoma; Kidney Cancer
- Interventions
- Durvalumab; Tremelimumab
- Arms
- Durvalumab + Tremelimumab with Nephrectomy · Experimental
- Enrollment
- 29
- Primary outcomes
- Patients with Dose Limiting Toxicity (DTL)
- Sponsor
- Moshe Ornstein
- Start
- Dec 20, 2016
- Primary completion
- Nov 6, 2020
- Results posted
- No
- Registry record
- NCT02762006 · updated Mar 18, 2024